Rossing P - Search Results

1

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Davies MJ, et al. Among authors: rossing p. Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30291106 Free PMC article.

2

Low birth weight. A risk factor for development of diabetic nephropathy?

Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving HH. Rossing P, et al. Diabetes. 1995 Dec;44(12):1405-7. doi: 10.2337/diab.44.12.1405. Diabetes. 1995. PMID: 7589846

3

Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.

Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes. 1995 May;44(5):489-94. doi: 10.2337/diab.44.5.489. Diabetes. 1995. PMID: 7729604

4

Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.

Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes Care. 1994 Nov;17(11):1247-51. doi: 10.2337/diacare.17.11.1247. Diabetes Care. 1994. PMID: 7821162

5

Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients.

Rossing P, Hommel E, Smidt UM, Parving HH. Rossing P, et al. Diabetes. 1993 May;42(5):715-9. doi: 10.2337/diab.42.5.715. Diabetes. 1993. PMID: 8482428

6

Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.

Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Yokoyama H, et al. Among authors: rossing p. Diabetes Care. 1996 May;19(5):441-5. doi: 10.2337/diacare.19.5.441. Diabetes Care. 1996. PMID: 8732706

7

Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.

Tarnow L, Rossing P, Nielsen FS, Hansen BV, Dyerberg J, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes Care. 1996 Dec;19(12):1382-7. doi: 10.2337/diacare.19.12.1382. Diabetes Care. 1996. PMID: 8941468

8

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH. Nielsen FS, et al. Among authors: rossing p. Diabetes. 1997 Jul;46(7):1182-8. doi: 10.2337/diab.46.7.1182. Diabetes. 1997. PMID: 9200654 Clinical Trial.

9

Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy.

Rossing K, Jacobsen P, Rossing P, Lauritzen E, Lund-Andersen H, Parving HH. Rossing K, et al. Among authors: rossing p. Diabetes Care. 1998 Nov;21(11):2007-15. doi: 10.2337/diacare.21.11.2007. Diabetes Care. 1998. PMID: 9802759

10

Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.

Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J. Parving HH, et al. Among authors: rossing p. Diabetes Care. 1999 Mar;22(3):478-83. doi: 10.2337/diacare.22.3.478. Diabetes Care. 1999. PMID: 10097932 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

739 results

Search Page